FDA Inspection 1234173 — Elementis Pharma GmbH
The FDA completed an inspection of Elementis Pharma GmbH on February 6, 2020 in Ludwigshafen Am Rhein. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- February 6, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Ludwigshafen Am Rhein (Germany)
Additional Details
Mutual Recognition Agreement (MRA)